Shagun Bindlish, MD, board member of the American Diabetes Association, discusses a recent clinical practice statement she coauthored published in the journal Obesity Pillars.
The inaugural digital issue of Patient Care focuses on the antiobesity and type 2 diabetes medications, semaglutide and tirzepatide.
The label expansion for semaglutide, based on the SELECT trial, includes data showing reduced risk of CV death of 15% and of death from any cause of 19%.
The novel unimolecular pill amycretin combines a GLP-1 and an amylin agonist and led to weight loss of 13% at 12 weeks in a phase 1 trial that just concluded, the company said.
Your daily dose of the clinical news you may have missed.
Obesity rates in the US over the 3 decades rose from 11.5% to 21.7% among boys and from 11.6% to 19.4% among girls. US men ranked 10th highest for obesity in 2022.
Analysis of heart registry data for SELECT trial-eligible adults (obesity, first MI, no diabetes) found an NNT of 49 and 5-year MACE incidence of 10.7%.
Viking's VENTURE trial met primary and all secondary endpoints, with GI-related TAEAs reported as mild/moderate and diminishing over the course of the 13-week study.
The statistically significant improvements in MASH with survodutide were seen without worsening fibrosis and included a relative reduction of steatosis of 30%.
Your daily dose of the clinical news you may have missed.